GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia

Zorginstituut Nederland has completed its assessment whether glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia in adults, adolescents and children aged 4 and over with diabetes mellitus can be included in the Medication Reimbursement System (GVS). The Zorginstituut's advice is to include glucagon nasal powder (Baqsimi®) in List 1B of the GVS. 

Registered indication

Glucagon nasal powder is indicated for the treatment of severe hypoglycaemia in adults, adolescents and children aged 4 and over with diabetes mellitus. It is available as a single-dose container with 3 mg of glucagon nasal powder. The recommended dose is 3 mg of glucagon administered in one nostril.

Interchangeability

In the GVS, the blood glucose-increasing medicinal product glucagon (Glucagen®, Glucagen hypokit®) is included for the indication ‘severe hypoglycaemia in diabetes mellitus’.

In the GVS, the classification of medicinal products into groups of interchangeability distinguishes between, among other criteria, medicinal products administered through injection and non-injection medicinal products.

For this reason, glucagon nasal powder and intramuscular glucagon are by definition not interchangeable. The Zorginstituut sees added value for glucagon nasal powder because of its ease of use in acute situations, which prevents underuse of intramuscular glucagon.

Zorginstituut's advice

The Zorginstituut advices the Minister of Medical Care to include glucagon nasal powder (Baqsimi®) on List 1B of the GVS.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.